Treatments of durvalumab plus the anti-VEGFR2 monoclonal antibody ramucirumab and pembrolizumab plus ramucirumab achieved objective responses in patients with advanced GC/GEJ in phase 1a/b studies showing promise for the anti-PD-L1/PD-1 plus VEGF inhibitor combination in these patients.16 This evidence concerns the gene PDCD1 and gastric cancer.